Annual FCF
-$35.83 M
-$6.45 M-21.94%
December 31, 2023
Summary
- As of February 12, 2025, RDHL annual free cash flow is -$35.83 million, with the most recent change of -$6.45 million (-21.94%) on December 31, 2023.
- During the last 3 years, RDHL annual FCF has risen by +$66.52 million (+64.99%).
- RDHL annual FCF is now -1207.70% below its all-time high of -$2.74 million, reached on December 31, 2010.
Performance
RDHL Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
N/A
June 1, 2024
Summary
- RDHL quarterly free cash flow is not available.
Performance
RDHL Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
N/A
June 1, 2024
Summary
- RDHL TTM free cash flow is not available.
Performance
RDHL TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
RDHL Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | - | - |
| 3 y3 years | +65.0% | - | - |
| 5 y5 years | -3.8% | - | - |
RDHL Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.9% | +45.0% | ||||
| 5 y | 5-year | -21.9% | +65.0% | ||||
| alltime | all time | -1207.7% | +65.0% |
RedHill Biopharma Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$35.83 M(+21.9%) | - | - |
| Jun 2023 | - | -$10.60 M(+47.5%) | -$26.25 M(-19.0%) |
| Mar 2023 | - | -$7.19 M(+196.8%) | -$32.40 M(+10.3%) |
| Dec 2022 | -$29.38 M(-54.9%) | -$2.42 M(-60.0%) | -$29.38 M(-29.7%) |
| Sep 2022 | - | -$6.05 M(-63.9%) | -$41.82 M(-23.7%) |
| Jun 2022 | - | -$16.74 M(+301.7%) | -$54.82 M(-3.8%) |
| Mar 2022 | - | -$4.17 M(-72.0%) | -$56.98 M(-12.6%) |
| Dec 2021 | -$65.16 M(-36.3%) | -$14.86 M(-22.0%) | -$65.16 M(+3.3%) |
| Sep 2021 | - | -$19.05 M(+0.8%) | -$63.05 M(+16.6%) |
| Jun 2021 | - | -$18.90 M(+53.0%) | -$54.08 M(-47.3%) |
| Mar 2021 | - | -$12.36 M(-3.1%) | -$102.66 M(+0.3%) |
| Dec 2020 | -$102.35 M(+149.9%) | -$12.75 M(+26.6%) | -$102.35 M(-1.1%) |
| Sep 2020 | - | -$10.07 M(-85.1%) | -$103.54 M(+1.1%) |
| Jun 2020 | - | -$67.48 M(+460.0%) | -$102.36 M(+125.2%) |
| Mar 2020 | - | -$12.05 M(-13.5%) | -$45.46 M(+11.0%) |
| Dec 2019 | -$40.95 M(+18.6%) | -$13.94 M(+56.7%) | -$40.95 M(+16.2%) |
| Sep 2019 | - | -$8.89 M(-15.9%) | -$35.25 M(+1.5%) |
| Jun 2019 | - | -$10.58 M(+40.4%) | -$34.73 M(+6.7%) |
| Mar 2019 | - | -$7.54 M(-8.4%) | -$32.55 M(-5.7%) |
| Dec 2018 | -$34.52 M(-24.9%) | -$8.23 M(-1.7%) | -$34.52 M(-14.7%) |
| Sep 2018 | - | -$8.38 M(-0.3%) | -$40.45 M(-7.4%) |
| Jun 2018 | - | -$8.40 M(-11.7%) | -$43.71 M(-3.2%) |
| Mar 2018 | - | -$9.51 M(-32.9%) | -$45.14 M(-1.8%) |
| Dec 2017 | -$45.95 M | -$14.17 M(+21.8%) | -$45.95 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$11.63 M(+18.3%) | -$42.02 M(+11.3%) |
| Jun 2017 | - | -$9.83 M(-4.8%) | -$37.77 M(+12.1%) |
| Mar 2017 | - | -$10.32 M(+0.9%) | -$33.69 M(+18.7%) |
| Dec 2016 | -$28.38 M(+45.8%) | -$10.23 M(+38.7%) | -$28.38 M(+17.4%) |
| Sep 2016 | - | -$7.38 M(+28.3%) | -$24.17 M(+17.4%) |
| Jun 2016 | - | -$5.75 M(+14.8%) | -$20.59 M(-2.1%) |
| Mar 2016 | - | -$5.01 M(-16.9%) | -$21.02 M(+8.0%) |
| Dec 2015 | -$19.46 M(+45.9%) | -$6.03 M(+58.8%) | -$19.46 M(+0.2%) |
| Sep 2015 | - | -$3.80 M(-38.6%) | -$19.42 M(-5.0%) |
| Jun 2015 | - | -$6.18 M(+79.3%) | -$20.45 M(+10.9%) |
| Mar 2015 | - | -$3.45 M(-42.4%) | -$18.43 M(+38.2%) |
| Dec 2014 | -$13.33 M(+54.0%) | -$5.99 M(+24.0%) | -$13.33 M(+35.9%) |
| Sep 2014 | - | -$4.83 M(+15.8%) | -$9.81 M(+34.5%) |
| Jun 2014 | - | -$4.17 M(-352.5%) | -$7.29 M(+38.9%) |
| Mar 2014 | - | $1.65 M(-167.0%) | -$5.25 M(-39.4%) |
| Dec 2013 | -$8.66 M(+25.5%) | -$2.47 M(+6.8%) | -$8.66 M(+11.8%) |
| Sep 2013 | - | -$2.31 M(+8.7%) | -$7.74 M(+12.3%) |
| Jun 2013 | - | -$2.13 M(+20.7%) | -$6.90 M(+4.2%) |
| Mar 2013 | - | -$1.76 M(+13.6%) | -$6.62 M(-4.1%) |
| Dec 2012 | -$6.90 M(+41.7%) | -$1.55 M(+5.9%) | -$6.90 M(+28.9%) |
| Sep 2012 | - | -$1.46 M(-20.9%) | -$5.35 M(+37.6%) |
| Jun 2012 | - | -$1.85 M(-9.4%) | -$3.89 M(+90.6%) |
| Mar 2012 | - | -$2.04 M | -$2.04 M |
| Dec 2011 | -$4.87 M(+77.8%) | - | - |
| Dec 2010 | -$2.74 M | - | - |
FAQ
- What is RedHill Biopharma annual free cash flow?
- What is the all time high annual FCF for RedHill Biopharma?
- What is RedHill Biopharma annual FCF year-on-year change?
- What is the all time high quarterly FCF for RedHill Biopharma?
- What is the all time high TTM FCF for RedHill Biopharma?
What is RedHill Biopharma annual free cash flow?
The current annual FCF of RDHL is -$35.83 M
What is the all time high annual FCF for RedHill Biopharma?
RedHill Biopharma all-time high annual free cash flow is -$2.74 M
What is RedHill Biopharma annual FCF year-on-year change?
Over the past year, RDHL annual free cash flow has changed by -$6.45 M (-21.94%)
What is the all time high quarterly FCF for RedHill Biopharma?
RedHill Biopharma all-time high quarterly free cash flow is $1.65 M
What is the all time high TTM FCF for RedHill Biopharma?
RedHill Biopharma all-time high TTM free cash flow is -$2.04 M